Journal of Endocrinology and Metabolism, ISSN 1923-2861 print, 1923-287X online, Open Access
Article copyright, the authors; Journal compilation copyright, J Endocrinol Metab and Elmer Press Inc
Journal website http://www.jofem.org

Original Article

Volume 4, Number 5-6, December 2014, pages 136-142

Significant Differences in Effects of Sitagliptin Treatment on Body Weight and Lipid Metabolism Between Obese and Non-Obese Patients With Type 2 Diabetes

Figures

Figure 1.
Figure 1. Change in body weight after the 6-month sitagliptin treatment in non-obese (BMI < 25) and obese groups (BMI ≥ 25). Presented boxes and bars indicate mean and SD, respectively. A statistical analysis was performed by the paired t-test.
Figure 2.
Figure 2. Change in HbA1c after the 6-month sitagliptin treatment in non-obese (BMI < 25) and obese groups (BMI ≥ 25). Presented boxes and bars indicate mean and SD, respectively. A statistical analysis was performed by the paired t-test.
Figure 3.
Figure 3. Changes in LDL-C (A), HDL-C (B), and TG (C), after the 6-month sitagliptin treatment in non-obese (BMI < 25) and obese groups (BMI ≥ 25). Presented boxes and bars indicate mean and SD, respectively. A statistical analysis was performed by the paired t-test.
Figure 4.
Figure 4. Correlation between change in serum TG and BMI at baseline. A statistical analysis was performed by the Pearson’s correlation test. R indicates correlation coefficient.

Tables

Table 1. Clinical and Biochemical Characteristic of Patients With BMI ≥ 25 and < 25
 
BMI ≥ 25 (n = 98)BMI < 25 (n = 75)P-value
BMI: body mass index; BP: blood pressure; eGFR: estimated glomerular filtration rate; HDL-C: high-density lipoprotein-cholesterol; LDL-C: low-density lipoprotein-cholesterol; TG: triglyceride.
Age (years)59.1 (14.5)69.6 (12.0)< 0.001
Sex (male/female)43/5544/310.054
Body height (cm)160.9 (9.3)159.9 (8.4)0.461
Body weight (kg)76.1 (13.9)56.1 (9.3)< 0.001
BMI (kg/m2)29.4 (4.6)21.8 (2.3)< 0.001
Systolic BP (mm Hg)129 (14)126 (16)0.146
Diastolic BP (mm Hg)72 (11)68 (12)< 0.05
Plasma glucose (mg/dL)191.6 (71.7)180.9 (65.2)0.323
HbA1c (%)7.8 (1.5)7.6 (1.3)0.344
LDL-C (mg/dL)111.7 (29.9)98.4 (23.1)< 0.05
TG (mg/dL)202.5 (130.5)130.7 (84.3)< 0.001
HDL-C (mg/dL)48.8 (12.1)53.7 (16.2)< 0.05
eGFR (mL/min/1.73 m2)82.6 (25.0)72.3 (19.7)< 0.01

 

Table 2. Other Prescribed Anti-Diabetic Drugs in Patients With BMI ≥ 25 and < 25
 
BMI ≥ 25 (n = 98)BMI < 25 (n = 75)
No other drugs23 (23.5%)10 (13.3%)
Sulfonylurea28 (28.6%)34 (45.3%)
Biguanide52 (53.1%)32 (42.7%)
Thiazolidinedione40 (40.8%)26 (34.7%)
α-glucosidase inhibitor35 (35.7%)25 (33.3%)
Glinide15 (15.3%)7 (9.3%)

 

Table 3. Changes in Blood Pressure, Plasma Glucose and eGFR at 6 Months After the Start of Sitagliptin Use
 
Values after 6 monthsChanges from baselineP-value
BMI: body mass index; BP: blood pressure; eGFR: estimated glomerular filtration rate; PG: plasma glucose.
BMI < 25 (n = 75)
  Systolic BP (mm Hg)124.1 (13.3)-1.2 (19.8)0.631
  Diastolic BP (mm Hg)70.4 (10.2)+3.1 (12.8)0.062
  PG (mg/dL)170.7 (67.6)-6.8 (74.9)0.472
  eGFR (mL/min/1.73 m2)71.2 (18.3)-0.9 (9.4)0.459
BMI ≥ 25 (n = 98)
  Systolic BP (mm Hg)126.0 (13.2)-3.0 (15.3)0.082
  Diastolic BP (mm Hg)71.2 (11.9)-1.0 (11.5)0.460
  PG (mg/dL)178.6 (64.3)-12.2 (61.0)0.462
  eGFR (mL/min/1.73 m2)80.2 (27.5)-2.6 (14.0)0.079